Who is moving to which position
Resolved 10 July 2026Incoming appointee
3 itemsDeparting officer
1 item“Next role stated” means the document names the position the person holds after stepping down. It does not necessarily mean they are leaving the company.
Expiration of term
Will retire as a director and is scheduled to become Chairman
Kuwajima Yutaka (桑島豊) is being nominated so that his extensive experience and achievements across a broad range of fields, as well as his contribution to strengthening the quality control system, can be applied to management. Otsuka Kenji (大津賀健史) is being nominated so that his experience and knowledge in formulating and implementing the medium-term management plan, financial and capital strategies, IR/SR activities, and DX strategy, among other areas, can be applied to management. Kusano Hiroko (草野弘子) is being nominated in the expectation that she will use her deep knowledge of the pharmaceutical supply chain as a whole and her management experience to contribute, from an independent standpoint, to sustainable growth and the strengthening of corporate governance.
The Business Development Division and the Human Resources and General Affairs Headquarters will be established effective 27 August 2026.
| Item | Details |
|---|---|
| Resolution date | 10 July 2026 |
| Scheduled Appointment Date | Effective 27 August 2026 (the election of candidates for directors who are not Audit and Supervisory Committee members is subject to approval at the 84th Annual General Meeting of Shareholders scheduled for 27 August 2026) |
| Date of departure | 27 August 2026 (Otsuka Yasunobu (大津賀保信) will retire as a director upon expiration of his term) |
| Name of appointee | Kuwajima Yutaka (桑島 豊), Otsuka Kenji (大津賀 健史), Kusano Hiroko (草野 弘子) |
| Appointee's new position | Candidate for director who is not an Audit and Supervisory Committee member, Candidate for director who is not an Audit and Supervisory Committee member, Candidate for outside director who is not an Audit and Supervisory Committee member |
| Appointee's previous position | Senior Executive Officer and Head of the Reliability Assurance Division, Executive Officer, CFO (Chief Financial Officer), Not disclosed |
| Appointee's date of birth | 8 February 1964, 5 November 1988, 1 September 1960 |
| Year the appointee joined the Company | 1986, 2023, Not disclosed |
| Name of departing officer | Otsuka Yasunobu (大津賀 保信) |
| Former position of departing officer | Representative director and chairman |
| New position of departing officer | Chairman |
| Reason for departure | Expiration of term |
| Whether the incumbent will remain in office | Will retire as a director and is scheduled to become Chairman |
| Reasons for appointment | Kuwajima Yutaka (桑島豊) is being nominated so that his extensive experience and achievements across a broad range of fields, as well as his contribution to strengthening the quality control system, can be applied to management. Otsuka Kenji (大津賀健史) is being nominated so that his experience and knowledge in formulating and implementing the medium-term management plan, financial and capital strategies, IR/SR activities, and DX strategy, among other areas, can be applied to management. Kusano Hiroko (草野弘子) is being nominated in the expectation that she will use her deep knowledge of the pharmaceutical supply chain as a whole and her management experience to contribute, from an independent standpoint, to sustainable growth and the strengthening of corporate governance. |
| Details of organizational changes | The Business Development Division and the Human Resources and General Affairs Headquarters will be established effective 27 August 2026. |
| Subject to Approval by the General Meeting of Shareholders | Yes. The election of candidates for directors who are not Audit and Supervisory Committee members is scheduled to be submitted for approval at the 84th Annual General Meeting of Shareholders scheduled for 27 August 2026. |
Items this document does not state (5)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The Company explained that the experience, achievements and knowledge of each new director candidate will be used in the management of the Company. It expects Kusano Hiroko (草野弘子) to contribute to sustainable growth and the strengthening of corporate governance. No reasons have been specified for the changes involving executive officers or the Representative Director, other than the expiration of their terms.